Interstitial Cystitis and Pelvic Floor Dysfunction: A Comprehensive Review

Lukban, James; Parkin, J.V.; Holzberg, Adam S.; Caraballo, Ricardo; Kellogg‐Spadt, Susan; Whitmore, Kristene

doi:10.1046/j.1526-4637.2001.002001060.x

Cited by 18 publications

(13 citation statements)

References 66 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1] The role of the central nervous system and pelvic floor dysfunction (PFD) in its pathogenesis and clinical manifestations has now been recognized. [2] We report our case to demonstrate the possible role of peripheral and central sensitization as a cause of visceral pain in IC and neuromodulation as a therapeutic modality for the same.…”

Section: Introductionmentioning

confidence: 99%

Treatment of interstitial cystitis/painful bladder syndrome as a neuropathic pain condition

2014

View full text Add to dashboard Cite

A lady of 52 years with painful bladder syndrome/interstitial cystitis (PBS/IC) presented with chronic pelvic pain, irritative voiding with sphincter dominance on urodynamics. 3 yrs of oral analgesics, antispasmodics and intravesical therapy was ineffective. We surmised her pain, and irritative voiding to be secondary to constant straining against a dysfunctional pelvic floor. We treated PBS/IC as a neuropathic phenomenon with a combination of neuromodulator medications and continuous caudal epidural analgesia to reduce the pain induced peripheral and central sensitisation. Botulinum toxin type A injection into pelvic floor muscles appeared to address their dysfuction. Clinical and urodynamics response was encouraging.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment of interstitial cystitis/painful bladder syndrome as a neuropathic pain condition

2014

View full text Add to dashboard Cite

show abstract

“…Interstitial cystitis (IC) is being re-examined within a broader context of chronic pelvic pain and pelvic floor dysfunction with the result that it is being recognized that the prevalence of IC is much higher than previously estimated [1,2]. It has long been evident that, whatever the cause, IC is a disease of the urothelium and the symptoms are triggered by urine [3].…”

Section: Introductionmentioning

confidence: 99%

Exogenous glycosaminoglycans coat damaged bladder surfaces in experimentally damaged mouse bladder

2005

View full text Add to dashboard Cite

Background: Interstital cystitis is often treated with exogenous glycosaminoglycans such as heparin, chondroitin sulphate (Uracyst), hyaluronate (Cystistat) or the semi-synthetic pentosan polysulphate (Elmiron). The mechanism of action is presumed to be due to a coating of the bladder surface to replace the normally present chondroitin sulphate and heparan sulphate lost as a result of the disease. This study used fluorescent labelled chondroitin sulphate to track the distribution of glycosaminoglycans administered intravesically to mouse bladder that had been damaged on the surface.

show abstract

“…7,8 Some data also suggest that physical therapy for urogenital pain syndromes is helpful. 9,10 Data continues to be limited in regards to management of short, painful pelvic floor muscles, such as is typically the case in women with vulvar symptoms and/or dyspareunia. [11][12][13][14][15] Until further data becomes available, physical therapists must rely on knowledge of basic science principles as they relate to muscle physiology, motor control, and pain mechanisms.…”

Section: Scope Of Problemmentioning

confidence: 99%